DNMT1 and acute myeloid leukemia: Despite these developments, Guadecitabine and other next-generation DNMT inhibitors failed to meet survival goals in Phase III AML studies, hence stressing the complexity of epigenetic reprogramming and the need for better biomarker-driven patient selection192.